Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9308 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.9308 |
High Similarity |
NPD1613 |
Approved |
0.9297 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.9225 |
High Similarity |
NPD3027 |
Phase 3 |
0.9219 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.873 |
High Similarity |
NPD1548 |
Phase 1 |
0.8571 |
High Similarity |
NPD4908 |
Phase 1 |
0.8503 |
High Similarity |
NPD2801 |
Approved |
0.8462 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8444 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8435 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8358 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8288 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8264 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8255 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8195 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8195 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8175 |
Intermediate Similarity |
NPD228 |
Approved |
0.8151 |
Intermediate Similarity |
NPD1512 |
Approved |
0.8146 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.812 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8102 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8088 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8079 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.806 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8026 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8013 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8013 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8013 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7929 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7926 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7925 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7914 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7914 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7911 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.791 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7907 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7815 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7815 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7812 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7806 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7801 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7778 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7764 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.774 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.774 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7724 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7718 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7718 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7716 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7707 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7669 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7669 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7656 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7655 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7652 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7651 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7651 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7647 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7635 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7619 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.761 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7609 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7603 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7597 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7597 |
Intermediate Similarity |
NPD37 |
Approved |
0.7597 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7582 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7578 |
Intermediate Similarity |
NPD290 |
Approved |
0.7564 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7564 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7564 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7557 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7552 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7552 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.755 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7531 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7519 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7517 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7517 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7516 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.75 |
Intermediate Similarity |
NPD968 |
Approved |
0.75 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7483 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7469 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7466 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7455 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.745 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7439 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7438 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7432 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7421 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7417 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7417 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7415 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7415 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7415 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7413 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7405 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7394 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7383 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7383 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7381 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7379 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7379 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7372 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7372 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7365 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7365 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7361 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7347 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7347 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7343 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7333 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7325 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7323 |
Intermediate Similarity |
NPD940 |
Approved |
0.7323 |
Intermediate Similarity |
NPD846 |
Approved |
0.7319 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7303 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7299 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7286 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7286 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7285 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7285 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7261 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7255 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7237 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7234 |
Intermediate Similarity |
NPD3225 |
Approved |
0.723 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7219 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7215 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7212 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7192 |
Intermediate Similarity |
NPD1240 |
Approved |
0.719 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7188 |
Intermediate Similarity |
NPD291 |
Approved |
0.7186 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7183 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7181 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7164 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7161 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7143 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7143 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7133 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7125 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7123 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7122 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7117 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7115 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7115 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7114 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7113 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7113 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7107 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7107 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7105 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7105 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7105 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7105 |
Intermediate Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7092 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7092
|
Intermediate Similarity |
NPD2231 |
Phase 2 |